Working… Menu
Trial record 1 of 2 for:    reprieve hiv
Previous Study | Return to List | Next Study

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults (REPRIEVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02344290
Recruitment Status : Active, not recruiting
First Posted : January 22, 2015
Last Update Posted : June 7, 2021
National Heart, Lung, and Blood Institute (NHLBI)
Kowa Pharmaceuticals America, Inc.
Gilead Sciences
Massachusetts General Hospital (MGH)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 24, 2023
Estimated Study Completion Date : March 26, 2023
Publications automatically indexed to this study by Identifier (NCT Number):